Sometimes the little things make the biggest differences.
A new research by UT Health San Antonio researchers found that the molecule, which is thousands of times less likely to kill the mucous membrane, is the most common childhood brain cancer.
This little molecule named MiR-584-5p is quite effective. MiR-584-5p expresses the tumor chemotherapy and radiation, which is recommended for the treatment of tumors in one tenth of doses, which says that research is headed by Manjiet Rao, PhD, Associate Professor of Cell Systems and Anatomy UT Health San Antonio and University Greehey Cancer Research Institute.
"Currently we have radiation and chemotherapy brains and the patients have a poor quality of life," said Dr. Radava. "When using this molecule we could have done 90% of these therapies.
MiR-584-5p is a very low level, or there is no Mediolablom. The amount of money found in healthy cells increases the cancer of the mechanisms that she will survive and she studies. "It can become a strong therapy for cancer treatment," said Dr. Rob.
Magazine Nature Communications Published comments on Oct 31.
Other anxiety about MiR-584-5p is that it is usually a high level of brain cells and not in other tissues. Therefore, when it is used in the brain as therapy to kill tumors, it will have a slight effect in healthy cells because these cells have never seen before. "They may not have treated the molecule as something strange," said Dr. Rua. The future therapy based on the molecule should be done well, "he said.
A major challenge for the treatment of brain tumors is the inability of cancer drugs to overcome the blood brain barrier, a protective mechanism that treats brain cancer. Because it is so sensitive, MiR-584-5p can give you the ability to cross the threshold in some patients. In the future, Dr. Rao said that the molecule can be transferred to the nanopartyl shift.
Besides Mediolablomia, the properties of MiR-584-5p are created by clinical drug Glioblastoma, aggressive and lethal adult brain cancer, Dr. Rob.
The MiR-584-5p technology was received by Dr. Rao and Nurhan Abdalatat, a doctorate, document published by the first author, which is listed as inventors. Dr Abdelfah graduated from Doctoral Laboratory in Doctorate and is a Postdoctoral staffer at Huston Methodist Center.
The second patent doctor issued by the US Patent and Trademark issued by Dr. Rao. Many commercialization business models are considered, including a possible start-up company, according to the Commercial Commercialization Office, UT Health San Antonio.
The Dr. Rao Research is supported by the San Antonio Foundation of the National Cancer Institute, Williams and Ella Owens Foundation, Texas and Max and Minne Tomarlin Walker Foundation by the Cancer Prevention and Research Institute.